Compare SUJA & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUJA | ARMP |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.3M | 199.7M |
| IPO Year | 2026 | 1996 |
| Metric | SUJA | ARMP |
|---|---|---|
| Price | $10.03 | $3.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $18.40 | $17.50 |
| AVG Volume (30 Days) | ★ 186.2K | 92.3K |
| Earning Date | 11-10-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.73 | N/A |
| Revenue Next Year | $12.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.59 | $2.75 |
| 52 Week High | $12.42 | $14.98 |
| Indicator | SUJA | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 46.21 |
| Support Level | $8.83 | $3.38 |
| Resistance Level | $10.94 | $4.07 |
| Average True Range (ATR) | 0.64 | 0.36 |
| MACD | -0.20 | 0.07 |
| Stochastic Oscillator | 7.73 | 52.83 |
Suja Life Inc operates a beverage platform focused on producing and selling products such as cold-pressed juices, wellness shots, and functional sodas. Its portfolio includes brands such as Suja Organic, Vive Organic, and Slice. The Company operates and manages its business in two operating segments, which are also reportable segments: i) Suja Core: It produces and distributes cold-pressed fresh juice and cold-pressed juice shots. ii) Emerging Brands: It consists of recently acquired or launched brands and products that are still in the early stages of revenue scale, market development, or distribution build-out. The majority of revenue is derived from Suja Core.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.